Acute administration of unacylated ghrelin has no effect on Basal or stimulated insulin secretion in healthy humans.

dc.contributor.author

Tong, Jenny

dc.contributor.author

Davis, Harold W

dc.contributor.author

Summer, Suzanne

dc.contributor.author

Benoit, Stephen C

dc.contributor.author

Haque, Ahrar

dc.contributor.author

Bidlingmaier, Martin

dc.contributor.author

Tschöp, Matthias H

dc.contributor.author

D'Alessio, David

dc.coverage.spatial

United States

dc.date.accessioned

2016-08-10T20:59:18Z

dc.date.issued

2014-07

dc.description.abstract

Unacylated ghrelin (UAG) is the predominant ghrelin isoform in the circulation. Despite its inability to activate the classical ghrelin receptor, preclinical studies suggest that UAG may promote β-cell function. We hypothesized that UAG would oppose the effects of acylated ghrelin (AG) on insulin secretion and glucose tolerance. AG (1 µg/kg/h), UAG (4 µg/kg/h), combined AG+UAG, or saline were infused to 17 healthy subjects (9 men and 8 women) on four occasions in randomized order. Ghrelin was infused for 30 min to achieve steady-state levels and continued through a 3-h intravenous glucose tolerance test. The acute insulin response to glucose (AIRg), insulin sensitivity index (SI), disposition index (DI), and intravenous glucose tolerance (kg) were compared for each subject during the four infusions. AG infusion raised fasting glucose levels but had no effect on fasting plasma insulin. Compared with the saline control, AG and AG+UAG both decreased AIRg, but UAG alone had no effect. SI did not differ among the treatments. AG, but not UAG, reduced DI and kg and increased plasma growth hormone. UAG did not alter growth hormone, cortisol, glucagon, or free fatty acid levels. UAG selectively decreased glucose and fructose consumption compared with the other treatments. In contrast to previous reports, acute administration of UAG does not have independent effects on glucose tolerance or β-cell function and neither augments nor antagonizes the effects of AG.

dc.identifier

http://www.ncbi.nlm.nih.gov/pubmed/24550190

dc.identifier

db13-1598

dc.identifier.eissn

1939-327X

dc.identifier.uri

https://hdl.handle.net/10161/12642

dc.language

eng

dc.publisher

American Diabetes Association

dc.relation.ispartof

Diabetes

dc.relation.isversionof

10.2337/db13-1598

dc.subject

Adolescent

dc.subject

Adult

dc.subject

Basal Metabolism

dc.subject

Blood Glucose

dc.subject

Drug Administration Schedule

dc.subject

Female

dc.subject

Ghrelin

dc.subject

Health

dc.subject

Humans

dc.subject

Insulin

dc.subject

Insulin-Secreting Cells

dc.subject

Male

dc.subject

Middle Aged

dc.subject

Young Adult

dc.title

Acute administration of unacylated ghrelin has no effect on Basal or stimulated insulin secretion in healthy humans.

dc.type

Journal article

duke.contributor.orcid

D'Alessio, David|0000-0003-4155-4870

pubs.author-url

http://www.ncbi.nlm.nih.gov/pubmed/24550190

pubs.begin-page

2309

pubs.end-page

2319

pubs.issue

7

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Duke

pubs.organisational-group

Duke Molecular Physiology Institute

pubs.organisational-group

Institutes and Centers

pubs.organisational-group

Medicine

pubs.organisational-group

Medicine, Endocrinology, Metabolism, and Nutrition

pubs.organisational-group

School of Medicine

pubs.publication-status

Published

pubs.volume

63

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Acute administration of unacylated ghrelin has no effect on Basal or stimulated insulin secretion in healthy humans.pdf
Size:
1.74 MB
Format:
Adobe Portable Document Format